The Retinoid X Receptor Agonist Bexarotene Relieves Positive Symptoms of Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial
Year: 2013
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
DOI: 10.4088/jcp.12m08160
Authors: Vladimir Lerner, Chanoch Miodownik, Anatoly Gibel, Pinchas Sirota, Ilan Bush, Hadi Elliot, Ruben Benatov, Michael S. Ritsner
Institution: Ben-Gurion University of the Negev
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Keywords: bexarotene, retinoid X receptor agonist, schizophrenia, schizoaffective disorder, positive symptoms, antipsychotic augmentation, lipid-lowering drugs, cholesterol, thyroxine, adverse effects, PANSS, quality of life, functioning, drug safety and tolerability, nuclear receptor signaling, treatment-resistant schizophrenia
Open Access status: closed
OpenAlex ID: W2062768595
